CD51/CD61+ Endothelial Microparticles Decrease in Diabetes Patients with Hypertension by Hu, Shuai-Shuai et al.
 International Journal of Sciences: 
Basic and Applied Research 
(IJSBAR) 
 
ISSN 2307-4531 
(Print & Online) 
 
http://gssrr.org/index.php?journal=JournalOfBasicAndApplied 
--------------------------------------------------------------------------------------------------------------------------- 
88 
 
CD51/CD61+ Endothelial Microparticles Decrease in 
Diabetes Patients with Hypertension 
Shuai-Shuai Hua, Hong-gang Zhangb*, Qiuju Zhangc, Ruijuan Xiud 
a,b,c,dInstitute of Microcirculation, Chinese Academy of Medical Sciences & Peking Union Medical College, 
Beijing, China 
aEmail: hushuaishuai87@gmail.com , bEmail: zhanghg1966126@imc.pumc.edu.cn 
cEmail: zhangqd20032003@163.com, dEmail: xiurj@imc.pumc.edu.cn 
 
Abstract 
Backgrounds: Type 2 Diabetes Mellitus (T2DM) and hypertension are commonly co-occurred and both diseases 
are related to endothelial dysfunction. Endothelial microparticles (EMPs) are shed from endothelial cells and can 
be found in condition of endothelial dysfunction. This study aimed to evaluate the circulating endothelial MPs 
(CD51/CD61+) levels in T2DM patients with or without hypertension and the correlation between endothelial 
MPs and clinical parameters. Methods and Results: 20 healthy control, 16 T2DM patients without hypertension 
and 11 T2DM patients with hypertension were recruited. CD51/CD61+ EMPs from all subjects were analyzed by 
flow cytometry. We found that, in the group of T2DM patients with hypertension, the absolute median number of 
CD51/CD61+EMPs was significantly decreased, compared with that in the healthy control and T2DM without 
hypertension groups. Furthermore, we conducted receiver operating characteristics (ROC) analysis to examine 
the accuracy of CD51/CD61+EMPs in the discrimination  between T2DM patients with hypertension and healthy 
control, showing the accuracy was 76.4%. In addition, we also found that the accuracy of CD51/CD61+EMPs was 
83.5% in the discrimination between T2DM patients with hypertension or without hypertension Conclusion: 
These findings identify CD51/CD61+EMPs as a potential biomarker to monitor endothelial dysfunction in T2DM 
patients with hypertension.  
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1. Introduction 
Over two-thirds of type 2 diabetes mellitus (T2DM) patients are found to coexist with hypertension [1]. 
Accumulating evidence shows that patients with these two diseases have an enhanced risk for cardiovascular 
disease [2]. Current knowledge shows that endothelial dysfunction is one of the initial event in the pathogenesis 
of cardiovascular diseases and is also associated with the pathology in diabetes and hypotension patients [3, 4]. 
Therefore, examining the endothelial function in patients with diabetes and hypertension might provide an 
alternative route to diagnose these diseases at very early stage. Endothelial microparticles (EMPs) are derived 
from endothelial cells in response to endothelial activation and apoptosis. EMPs are closely associated with 
endothelial dysfunction in diabetes or hypertension [5,6]. However, there is a lack of specific biomarkers to 
monitor endothelial dysfunction in condition of diabetes and hypertension. The current study aimed at studying 
CD51/CD61+EMPs in diabetes patients with or without hypertension to identify a biomarker to monitor 
endothelial function in diabetes patients with hypertension. 
2. Methods 
2.1 Study subjects 
In total, 27 T2DM patients were recruited, including 16 T2DM patients without hypertension and 11T2DM with 
hypertension patients. Diagnose of diabetes was based on 1999 World Health Organization diagnostic criteria for 
diabetes mellitus. Hypertension was diagnosed as either a systolic BP≥140 mmHg or diastolic (DBP) ≥90 mm Hg 
supine arterial blood pressure (BP) (after 10 minutes of rest), and was measured twice using a mercury 
sphygmomanometer. Patients with a history of chronic renal failure requiring dialysis, hepatic or hematologic 
disorders, or inflammation, autoimmune, malignant diseases, type 1 diabetes and coronary heart diseases were 
excluded. 20 healthy subjects were recruited. Healthy subjects were included if they had no known history of 
medical illness, normal blood pressure (<140/90 mmHg) and normal blood glucose, and appeared healthy in a 
physical examination. The protocol regarding this study was approved by the Institutional Review Board of the 
medical institution (Ethics committee at institute of Microcirculation Peking Union Medical College &Chinese 
Academy of Medicine Science) and verbal informed consent was received from each study subject before entering 
the study. Clinical and laboratory data were collected from all subjects as shown Table 1. 
2.2 Isolation and measurement of endothelial microparticles (EMP) 
For microparticles isolation and measurements, the protocol was applied as previous experiments [7]. For the 
endothelial microparticles flow cytometry assay, platelet-poor plasma (50 µl) was incubated with fluorescein 
isothiocyanate-labelled (FITC) anti-CD51/CD61 (integrin alpha v beta3, 110519. eBioscience), the samples were 
incubated at room temperature for 20 min, diluted with 1 ml of phosphate-buffered saline, and analyzed by flow 
cytometry (Accuri C6, Accuri Cytometers). An isotype control antibody was used as a negative control in all 
measurements. EMP was defined as CD51/CD61+positive particles. Values are reported as counts per µl of 
peripheral blood. The laboratory personnel that performed these assays were blinded to all clinical data and the 
study participants. 
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2.3 Statistical analysis 
GraphPad Prism version 8 was used for statistics calculation and plots. D’A gostino-Pearson test was used to 
measure data normality. One-way ANOVA testing followed by Tukey test was applied for normal distributed data 
while one-way Kruskal-Wallis analysis followed by Manny-Whitney U test was applied to data which was not 
normally distributed among three groups. The chi-square test was used to compare quantitative and categorical 
variables. Univariate correlation analysis was performed by Spearman’s rank correlation coefficients (r). Receiver 
Operating Characteristic (ROC) analysis was performed to assess the accuracy of the diagnostic test of 
CD51/CD61+EMP in DM with hypertension patients. P values<0.05 were considered significant. All data is 
expressed as mean ± SD or otherwise identified in the table. 
3. Results and Discussion 
3.1 Clinical characteristics and CD51/CD61+EMPs analysis of study subjects 
Clinical data of both health control and patients’ groups are described in Table1. The groups are matched by 
gender. Healthy control group and T2DM without hypertension group also are matched by BMI status. The mean 
age of healthy control was younger than that of the T2DM patients groups (p<0.0001) including T2DM patients 
with or without hypertension. The BMI index was higher in T2DM with hypertension groups (p<0.001) than that 
of the healthy control and T2DM without hypertension group (p<0.05). As figure 1 shows the numbers of 
CD51/CD61+EMPs were lower in the T2DM with hypertension group than that of the healthy control (p<0.05) 
and T2DM without hypertension group (p<0.01). There was no significantly statistics of CD51/CD61+EMPs 
between healthy control and T2DM patients without hypertension. 
Table 1: Clinical data of experimental subjects 
Characteristics Control DM-HP(-) DM-HP(+) 
Age 36.00±8.53 55.69±9.11aP 59.18±11.81aP 
Gender(Female/male) 13/7 7/9 4/7 
BMI(kg/m2) 22.49±1.77 24.05±2.76 26.67±3.02 aP bP 
Blood Glucose(mmol/l) - 9.77±3.28 10.5±3.73 
Hemoglobin A1C% - 9.64±2.29 8.7±1.84 
Medicine No    
Insulin - 5 5 
Metformin - 1 1 
Sulfonylurea - - 2 
Acarbose - 2 2 
Repaglinide - - 37 
B-blocker - 0 1 
Diuretic - 0 1 
ACE inhibitor/ARB - 0 2 
CCB - 0 2 
Values are mean ± SD, or number. BMI, body mass index; ACE-I/ARB, angiotensin-converting enzyme 
inhibitor/angiotensin II receptor blocker; CCBs, calcium channel blockers; DM-HP(-),diabetes without 
hypertension; DM-HP(+), Diabetes with hypertension; A value of P < 0.05 was considered significant. aP 
compared with control, bP: compared with diabetes without hypertension. 
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Figure 1: Diabetic patients with hypertension had significantly decreased number EMPs compared to healthy 
control and Diabetic patients without hypertension. The difference between groups was analysed using a Mann-
Whitney U test. (* p<0.05, **p<0.01). 
3.2 Correlations between the number of CD51/CD61+EMP and clinical parameters 
To investigate the correlation among the CD51/CD61+EMP levels and age and BMI (Figure 2). All the subjects 
were included (healthy control and two patients groups), no correlation were observed between CD51/CD61+EMP 
levels and age or BMI (all p>0.05). Considering only patients groups, no correlation were observed between 
CD51/CD61+ EMP levels and blood glucose level or hemoglobin A1c level (all p>0.05). 
 
Figure 2: The correlation between CD51/CD61+EMP and clinical parameters. (A, B, C, D ) no significant 
association was detected between CD51/CD61+EMP and age, BMI, blood glucose and HbA1c%. 
International Journal of Sciences: Basic and Applied Research (IJSBAR) (2020) Volume 51, No  2, pp 88-94 
92 
 
3.3 Usefulness and Accuracy of CD51/CD61+EMP as a monitor endothelial dysfunction factor in DM with 
hypertension 
To assess the accuracy of CD51/CD61+ EMP to monitor endothelial dysfunction in T2DM with hypertension 
patients, ROC curve was performed and shown in Figure 3. To diagnose patients between healthy control and 
T2DM with hypertension patients, the area under the ROC curve was 0.764 (95% CI, 0.592-0.935, P=0.02). The 
optimal cut off value was 20.14 counts/µl, with sensitivity and specificity values of 100% and 45%, respectively. 
To distinguish between T2DM with hypertension and T2DM without hypertension patients, the area under the 
ROC curve was 0.835 (95% CI, 0.679-0.991, P=0.0036). The optimal cut off value was 10.76 counts/µl, with 
sensitivity and specificity values of 81.82% and 75%, respectively. 
 
Figure 3: ROC curve analysis to determine the threshold of CD51/CD61+EMPs. (A). CD51/CD61+EMPs at a 
cut off 20.14 counts/µl ,p<0.05, could be discriminated between healthy control and T2DM patients with 
hypertension with 76.4% accuracy. (B) CD51/CD61+EMPs at a cut off 10.76 counts/µl ,p<0.01, could be 
discriminated between healthy control and T2DM patients with hypertension with 83.5% accuracy. 
4. Discussion 
We demonstrated that the decreased level of circulating CD51/CD61+ EMP is associated with DM patients with 
hypertension. According to ROC analysis, CD51/CD61+ EMPs show high sensitivity to discriminate T2DM with 
hypertension patients from healthy control. Furthermore, CD51/CD61+ EMP shows high sensitivity and 
specificity to discriminate between T2DM patients with or without hypertension. CD51/CD61+ EMPs are not 
correlated with age, BMI, blood glucose and hemoglobin A1c, which shows CD51/CD61+ EMPs are an 
independent biomarker to monitor endothelial dysfunction in T2DM with hypertension patients. Compared with 
previous studies, these studies show CD144, CD105, CD31, CD62E EMP significantly increased in T2DM 
patients [5, 8]. In our study, there is no significant difference of CD51/CD61+ EMP between healthy control and 
DM patients, the possible reason is that EMP is a heterogenous population [9] and EMP shows the ambivalent 
role in vascular diseases (8). Our study suggests the different role of CD51/CD61+ EMP in T2DM compared with 
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other EMP biomarkers. Our previous study shows [10] that there is no significant difference of CD51/CD61+ 
EMPs numbers between healthy control and hypertension patients without diabetes, which indicates that 
CD51/CD61+ could be a specific biomarker to monitor endothelial dysfunction in T2DM with hypertension 
patients. In our previous study [10], we also demonstrated that the number of CD51/CD61+EMP was significantly 
high in obese hypertension patients, which could be indicating that CD51/CD61+EMP is involved in different 
pathophysiological roles in hypertension patients with obesity or with T2 DM.  
5. Conclusion 
The findings of this study indicate that CD51/CD61+ EMP can be used a specific EMP biomarker to monitor 
endothelial dysfunction in T2DM with hypertension patients.  
6. Limitations of the study 
There are some limitations in our study: 1) It is necessary to recruit large numbers of diabetes, hypertension and 
diabetes with hypertension patients to validate our results.2) The pathophysiological role of CD51/61+  EMP in 
hypertension patients with diabetes or with obesity needs to be further investigated. 
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